In an intriguing example designed to exploit this phenomenon, investigators modified the structure of pemetrexed (PMX), a folate antimetabolite used in treatment of lung and bladder cancer, to favor uptake by the proton-coupled folate transporter (PCFT/ SLC46A1) [50]. The gene discussed is SLC46A1; the disease is urinary bladder cancer.